CADTH Releases Intervention Tools aimed at influencing behaviour, regarding the prescribing and use of Proton Pump Inhibitors
April 25, 2007
OTTAWA — The Canadian Agency for Drugs and Technologies in Health (CADTH) today announced the release of Optimal Therapy Reports and Intervention Tools for the prescribing and use of proton pump inhibitors (PPIs) through its Canadian Optimal Medication Prescribing and Utilization Service (COMPUS).
Barb Shea, Vice-President of CADTH’s COMPUS program, noted the significance of this achievement.
“COMPUS Optimal Therapy Reports and Tools support health care providers, decision makers and consumers in making decisions on drug therapy. We are confident that through the uptake and adoption of reliable information on drug prescribing and use, health outcomes in Canada can be improved, and health care resources targeted more effectively.”
The Optimal Therapy Reports on PPIs include a scientific report containing evidence-based statements for PPI use in gastroesophageal reflux disease (GERD), dyspepsia and peptic ulcer disease, as agreed upon by the COMPUS Expert Review Panel on PPIs; economic models and conclusions for the treatment of dyspepsia, heartburn associated with GERD, and the prevention of non-steroidal anti-inflammatory drug (NSAID)-induced gastrointestinal complications; a literature review of interventions for the appropriate prescribing of PPIs; a current-practice analysis of the prescribing and use of PPIs in Canada; a gap analysis comparing current practice with the evidence; and a report on the COMPUS selection of interventions for the PPI project.
Intervention tools — designed to influence behaviour change — have also been released to assist jurisdictions in implementing COMPUS information. The first of these tools comprise components of an academic detailing program that can be used by health care providers and consumers. Other intervention tools will be released in May and June of this year. All COMPUS reports and tools can be found on the CADTH web site at www.cadth.ca.
For more information, visit www.cadth.ca or contact:
Janet Crain, Senior Communications Advisor
Canadian Agency for Drugs and Technologies in Health
Tel: (613) 226-2553 E-mail: janetc@cadth.ca
The Canadian Agency for Drugs and Technologies in Health (CADTH) is a national body that provides Canada’s federal, provincial, and territorial health care decision makers with credible, impartial advice and evidence-based information about the effectiveness and efficiency of drugs and other health technologies.